NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

TSX · Drug Manufacturers - Specialty & Generic · CAD

Canopy Growth Corporation (WEED.TO) Stock Analysis

Canopy Growth Corporation (WEED.TO) is a Drug Manufacturers - Specialty & Generic stock listed on TSX and quoted in Canadian Dollar.

Last Updated: October 21, 2026

WEED.TO

CA$0.94

−CA$0.07 (−6.93%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare WEED.TO with… →

WEED.TO Key Statistics

As of Oct 21, 2026
Trading
Open
CA$1.01
Previous Close
CA$1.01
Day's Range
0.93–1.01
52-Week Range
0.93–3.28
Volume
2.16M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.37
Valuation
Market Cap
CA$422.34M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.44
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.62
Financials (FY)
Revenue (FY)
CA$284.60M+5.80%
Net Income (FY)
−CA$262.91M
Profit marginThe share of revenue left as profit after all costs and taxes.
−79.22%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
423.04M
1-Year Return
−50.79%
Dividend and dates
Earnings Date
November 6, 2026estimated
Avg Volume
724.69K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, WEED.TO closed at CA$0.94, −50.79% over 1 year.

Canopy Growth Corporation (WEED.TO) has a market capitalization of CA$422.34M.

In fiscal 2025, WEED.TO reported revenue of CA$284.60M.

WEED.TO Stock Return by Calendar Year

Canopy Growth Corporation (WEED.TO) 10-year return: what CA$10,000 became

1 year
CA$10,000 CA$4,921
−50.79%
5 years
CA$10,000 CA$54
−99.46%
10 years
CA$10,000 CA$138
−98.62%

If you had invested CA$10,000 in Canopy Growth Corporation (WEED.TO) 10 years ago, at the close on October 21, 2016, it would have been worth CA$138 at the close on October 21, 2026: −98.62% in total, −34.85% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−39.74%
2025−60.41%
2024−41.72%
2023−78.47%
2022−71.56%
2021−64.75%
2020+14.68%
2019−25.40%
2018+23.10%
2017+225.38%
2016 (partial year)+134.96%

As of October 21, 2026.

WEED.TO Revenue and Earnings by Fiscal Year

FY ends March
Fiscal yearRevenueNet incomeNet margin
2025CA$284.60M−CA$262.91M−92.4%
2024CA$269.00M−CA$508.88M−189.2%
2023CA$297.15M−CA$693.68M−233.4%
2022CA$333.25M−CA$3.28B−983.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025CA$284.60MCA$69.67M−CA$73.11M−CA$262.91M−92.4%
2024CA$269.00MCA$79.51M−CA$66.39M−CA$508.88M−189.2%
2023CA$297.15MCA$80.88M−CA$162.73M−CA$693.68M−233.4%
2022CA$333.25M−CA$63.53M−CA$395.78M−CA$3.28B−983.7%

Annual figures as reported, in the company's reporting currency. As of March 31, 2026.

WEED.TO Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricWEED.TODrug Manufacturers - Specialty & Generic medianvs median
P/S ratio1.442.1032% below
Profit margin−79.22%−8.14%71.1 pts below

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Analysis

Data-derived

Company Overview

Canopy Growth Corporation (WEED.TO) carries a market capitalisation of CA$422.34M. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. The company reports 1,128 employees.

Over the past 52 weeks the price has ranged from CA$0.93 to CA$3.28. WEED.TO last closed at CA$0.94 on October 21, 2026. That is −CA$0.07 (−6.93%) against the previous close. The latest close sits 1.08% above that 52-week low.

Financial Health

In fiscal 2025, Canopy Growth Corporation reported revenue of CA$284.60M. That is +5.80% against the prior fiscal year, when revenue was CA$269.00M. The same year closed with a net loss of CA$262.91M. Profit margin runs at −79.22%. That is 71.1 percentage points below the Drug Manufacturers - Specialty & Generic median of −8.14%. Trailing earnings per share are −0.62.

Across the 4 fiscal years on file, revenue moves from CA$333.25M in 2022 to CA$284.60M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 1.44 times revenue. On price-to-sales that is 31.51% below the Drug Manufacturers - Specialty & Generic median of 2.1. 97 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 2.37. Annualized volatility over the trailing 10 years is 101.94%. The trailing one-year total return is −50.79%. Measured over 10 years, that is −34.85% a year compounded.

Growth & Income

The record shows no dividend for WEED.TO.

The strongest complete calendar year on file is 2017 at +225.38%; the weakest is 2023 at −78.47%. Of the 9 complete calendar years on file, 3 finished higher. 2026 is still running; the total return is −39.74% year to date.

Peer Comparison

Canopy Growth Corporation (WEED.TO) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Canopy Growth Corporation WEED.TO CA$422.34M —
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

Market caps are shown in each company's own trading currency, without conversion, and the peers are listed in order of these unconverted figures.

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Canopy Growth Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Canopy Growth Corporation

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-related products for medical and adult use in Canada, Germany, the United States, and internationally. The company operates through two segments, Cannabis and Storz & Bickel. It also provides vaporizers and accessories; dried flower and pre-rolled joints, oil, and vapes and beverages; extracts and concentrates, such as softgel capsules; and cannabis edibles, including gummies. In addition, the company operates e-commerce shop; medical cannabis online distribution platform; and an online medical cannabis clinic. It sells its products under the Tweed, 7ACRES, Deep Space, HiWay, Maitri, Twd., Spectrum Therapeutics, Canopy Medical, Abba Medix, Storz & Bickel, Wana, and Claybourne, Apollo, Canada House, R'belle, LowKey, MTL Cannabis, DeeLish, DOJA brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.

Visit website →